Effect of Unani formulation on Diabetes Mellitus in In-Vitro studies on HepG2 cell line along with In-vivo Pilot Clinical Study. - NI

Central Council for Research in Unani Medicine(CCRUM)0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年9月18日

试验速览

暂无简介。

•Patients of any sex aged of 30-65 years.
•Fasting plasma glucose levels between 126 and 175 mg/dL (or)
•Post Prandial plasma glucose levels between 200 and 250 mg/dL (or)
•HbA1c level between 6.5 and 8% (as per ADA 2010 Criteria)
•Presence of any of the following symptoms and signs of diabetes mellitus: Polydipsia, Polyuria, Nocturia, Giddiness, Fatigue, Loss of Weight, Polyphagia & Loss of Libido

•Subjects with FPG level >175 mg/dL and/ or PP plasma glucose level >250 mg/dL and/ or HbA1c >8%
•Subjects on Insulin therapy.
•Type 2 DM with complications/ Type 1 DM
•Significant pulmonary/ cardiovascular/ hepato-renal dysfunction
•Known cases of immune-compromised states (HIV/ AIDS, etc.)/ Malignancies
•Obese subjects (BMI >30)
•Pregnant and lactating women
•Drug addicts/ Alcoholics
•Patient not willing to attend treatment schedule regularly

发起方

Central Council for Research in Unani Medicine(CCRUM)